Family offices didn’t just come back to the deal table in April – they showed up with term sheets in one hand and stethoscopes in the other.
Healthcare Becomes the New Family Office Heirloom
After a cautious March tied to geopolitical jitters around the Iran conflict, family offices snapped back into action in April, logging 55 direct investments versus 39 the prior month, according to Fintrx data shared with CNBC. Nearly one‑third of those checks went into healthcare and life sciences, effectively turning the sector into the new “must‑have” asset class between the art collection and the ski chalet.
The renewed momentum follows a broader pattern: family offices have been steadily growing as a force in private markets, now overseeing trillions in assets and increasingly bypassing traditional funds to back companies directly. Surveys show healthcare innovation ranks just behind artificial intelligence as a top thematic focus, with 50% of family offices flagging it as a priority, compared with 65% for AI. For wealthy families, the future, it seems, is part chips, part clinical trials.
From Waiting Room To Deal Room
If these healthcare bets feel personal, that’s because they often are. CNBC notes that many family offices cite direct experiences – from navigating complex diagnoses to losing loved ones – as catalysts for their investment theses in therapeutics, diagnostics, and digital health. Dolby Family Ventures, for instance, joined a €53 million Series B round for Exciva, an Alzheimer’s agitation treatment company, a cause linked to the late Ray Dolby’s own battle with the disease.
This mix of lived experience and long‑dated capital is giving rise to a distinct investor type: part venture capitalist, part legacy architect. Unlike traditional PE funds marching to a 10‑year clock, family offices can underwrite therapies and platforms whose payoff looks more like a medical timeline than a quarterly earnings call. In the process, they are turning the family narrative – once written in real estate and public stocks – into one that also runs through biotech labs and AI‑enabled clinics.
The April Deals: AI Doctors And Cancer Codebreakers
April’s return to form wasn’t just about deal volume; it was about where the money flowed. Emerson Collective, Laurene Powell Jobs’ investment and philanthropy platform, backed two of the month’s headline healthcare transactions: Ultralight and Stipple Bio. Ultralight, an AI‑driven software platform for personalized healthcare solutions, raised about $9.3 million, effectively positioning itself as a digital co‑pilot for clinicians navigating increasingly complex patient data.
On the therapeutics side, Stipple Bio secured a $100 million Series A, co‑led by Andreessen Horowitz, to advance targeted cancer treatments. The round underscored how quickly family offices have moved from watching oncology breakthroughs on conference stages to helping write the cap tables behind them. Together, these deals illustrate the barbell strategy taking hold in healthcare: software platforms that make the system smarter on one end, and precision therapies that may redefine standards of care on the other.
Enter Naya Therapeutics: Astatine, Alpha And Boardroom Signal
Into this backdrop steps Naya Therapeutics, a clinical‑stage company building a portfolio around astatine‑211–based alpha therapeutics for hard‑to‑treat cancers. In March, Naya announced a “world‑class” board of directors, adding Ely Benaim, MD, Margarita Chavez, JD, Anne Lauvergeon, PhD, and Rahul Singhvi, PhD, MBA – a lineup that blends deep drug‑development, deal‑making, industrial, and company‑building experience. The new directors join a leadership platform anchored by CEO Daniel Teper, a veteran of oncology and regenerative medicine ventures under the broader NAYA Biosciences umbrella.
For family offices and top‑tier biotech VCs, this kind of governance reset functions as a bright, flashing due‑diligence beacon. Astatine‑211 has become one of the more closely watched isotopes in targeted radiopharmaceuticals, and Naya’s push to solidify its early leadership in the space – including U.S. supply chain partnerships and a bispecific antibody pipeline – has put the company squarely on the meeting agendas of healthcare‑focused family offices and specialist venture funds exploring their next wave of oncology exposure.
Over the past several weeks, Naya’s management and board have been in active discussions with these capital providers about the company’s next phase of development, from advancing lead candidates through key clinical milestones to scaling manufacturing and commercial infrastructure suitable for a new class of alpha therapies. For families already leaning into healthcare as a multigenerational theme, the pitch is straightforward: marry a differentiated radiopharmaceutical platform with a board that has lived through drug approvals, M&A cycles, and public‑market transitions, and you have a candidate not just for a single exit, but for a franchise.
AI Still Wears The Sector Crown
Healthcare’s April glow‑up didn’t happen in a vacuum. For much of the past year, AI has been the undisputed star of family office portfolios, topping CNBC’s Family Office 15 ranking by deal count and dominating JPMorgan’s survey of thematic priorities. Hillspire, the office for former Google CEO Eric Schmidt, led the 2025 deal‑makers list with a string of AI‑heavy bets, from voice technology to fusion energy, setting a blueprint for other wealthy families eager to align with the next computing wave.
Yet the latest data show that healthcare is increasingly sharing the spotlight. In CNBC’s reporting, AI, technology, and software collectively captured more than a third of family office transactions, with healthcare and biotech emerging as the next‑largest buckets. If last year’s playbook was “AI everywhere,” April’s version reads more like “AI everywhere – especially in your doctor’s office.”
Private Capital Steps In As Public Funding Steps Back
One reason healthcare is drawing more family‑office firepower is that federal research dollars aren’t exactly racing higher. An April budget proposal from the Trump administration calls for cuts to National Institutes of Health funding, raising questions about who will bankroll the next generation of drugs, devices, and diagnostics. Into that gap steps private wealth – patient, mission‑driven, and increasingly data‑informed.
This is not purely altruism, of course. Healthcare and biotech have long offered asymmetric upside when science, regulation, and market timing line up – a fact not lost on families whose fortunes were often built on earlier waves of disruption, from generics to vaccines. For them, backing platforms that can lower costs, improve outcomes, or tackle aging itself is both a business proposition and a way to future‑proof the family story.
What April Signals For The Rest Of 2026
The April rebound follows a choppy stretch. Family offices entered 2026 on a subdued note, with January and December deal volumes down sharply year‑over‑year as tariff concerns and geopolitical shocks kept risk appetite in check. February brought a surge in AI‑focused investments, and now April has delivered a clear rotation toward healthcare, suggesting that risk is back on – selectively.
If the pattern holds, the remainder of 2026 could see family offices leaning harder into themes that marry durable demand with technological leverage: AI‑assisted diagnostics, mental health platforms, women’s health, neurodegenerative disease – and alpha radiotherapies like those under development at Naya. That doesn’t mean every pitch deck with a molecule and a machine‑learning model gets a term sheet, but it does mean founders in those lanes will find a growing audience that thinks in generations, not quarters.
For investors watching from the public markets, the message is subtle but clear: when the world feels uncertain, the ultra‑wealthy are still willing to write big checks – they’re just writing them to companies trying to fix the human body, with platforms like Naya’s sitting squarely in that crosshairs.
The Sources
Here’s a clean, numbered list of the key sources used, with links:
- CNBC – “Family office deal-making rebounds in April with healthcare bets”
https://www.cnbc.com/2026/05/07/family-office-dealmaking-april-healthcare-bets.htmlcnbc - Longbridge / syndicated CNBC piece – “Family office deal-making rebounds in April with healthcare bets”
https://longbridge.com/en/news/285546281longbridge - CNBC – “Inside Wealth Family Office 15: Most active investment firms and themes”
https://www.cnbc.com/2026/02/12/inside-wealth-family-office-15.htmlcnbc - CNBC – “Family office deals cooled off in December, but heirs still took risks”
https://www.cnbc.com/2026/01/08/family-office-deals-bets-december.htmlcnbc - CNBC – “Where billionaires’ investment firms placed their bets in 2025”
https://www.cnbc.com/2026/02/05/billionaire-investing-family-office.htmlcnbc - CNBC – “Family offices double down on AI investments as startup valuations reset”
https://www.cnbc.com/2026/03/05/family-offices-ai-investments.htmlcnbc - NBC News – “Family offices ramp up dealmaking in June with bets on biotech”
https://www.nbcnews.com/business/personal-finance/family-offices-ramp-deal-making-june-bets-biotech-rcna217299nbcnews - Dakota – “February 2026 Family Office Investments”
https://www.dakota.com/reports-blog/february-2026-family-office-investmentsdakota - The FO Pro – “Deal Round-Up: Family Offices Make Moves in Health Care, Manufacturing and Public Markets”
https://thefopro.com/deal-round-up-family-offices-make-moves-in-health-care-manufacturing-and-public-markets/thefopro - Future Family Office – “Family Office Dealmaking Rebounds With Big Healthcare Bets”
https://futurefamilyoffice.net/news/family-office-dealmaking-rebounds-with-big-healthcare-bets/futurefamilyoffice - CNBC – “Another alliance of health care and AI signals why pharma stocks could be back”
https://www.cnbc.com/2026/01/20/another-alliance-of-health-care-and-ai-signals-why-pharma-stocks-could-be-back.htmlcnbc - Naya Therapeutics / Access Newswire – “NAYA Therapeutics Announces World-Class Board of Directors”
https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-announces-world-class-board-of-directors-1148490accessnewswire - LinkedIn – Naya Therapeutics post on world-class board announcement
https://www.linkedin.com/posts/naya-therapeutics_naya-therapeutics-announces-world-class-board-activity-7439683577744715776-lU_wlinkedin - LinkedIn – Daniel Teper post on Naya, astatine‑211 and new board members
https://www.linkedin.com/posts/danielteper_astatine211-activity-7440011740693676032-ysOglinkedin - Yahoo / GlobeNewswire – “NAYA Biosciences Announces Nomination of New Board Members”
https://finance.yahoo.com/news/naya-biosciences-announces-nomination-board-141500586.htmlfinance.yahoo
